RJ Hamster
(Nasdaq: TLSA) Lights Up Our Radar Behind 5 Explosive…
Any content you receive is for information purposes only. Always conduct your own research.
(Nasdaq: TLSA) Lights Up Our Radar Behind 5 Explosive Potential Catalysts (Strong Analyst Target)
*Click Here To Get Our Alerts Faster Via SMS*
January 25th
Greetings Readers,
In the field of advanced immunology, one emerging biotech company is quietly reshaping the way researchers think about treating chronic neuroinflammatory conditions.
Its scientists are developing a new approach that targets the immune system through a novel delivery method designed to reduce inflammation while preserving natural defense mechanisms.
Early clinical data highlight meaningful patient outcomes and validation from respected medical institutions.
With continued progress across key trials, this company could soon redefine therapeutic strategies for disorders long resistant to conventional care—making it a story worth following more closely.
And as an analyst target points to potential triple-digit upside, this under-the-radar Nasdaq idea tops our watchlist Monday:
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)
Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
The Company’s innovative nasal approachhas the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.
Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date.
And based on several potential catalysts, (Nasdaq: TLSA) has taken over the top spot on my watchlist. Check them out:
#1. The Company Celebrates Peer-Reviewed Success Validating Foralumab’s Clinical Promise.
#2. An Analyst $8 Target Suggests Triple-Digit Potential Upside From Current Chart Levels.
#3. 2 Separate Insiders Make Aggressive Purchases Highlighting What Could Be Significant Confidence In The Company.
#4. A Major Milestone Is Achieved With First Patient Dosing In Critical Phase 2 Trial.
#5. The Company Recently Announced It Will Advance A 2nd Asset Following An Explosive Industry Acquisition.
But more on those in a second…
Tiziana Life Science Full Company Breakdown
Tiziana Life Sciences is a clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory.
Their clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS.
Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
Company Background
Tiziana’s mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.
The Company’s lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Foralumab is the only fully human anti-CD3 monoclonal antibody under clinical development and is expected to minimize adverse immune responses in patients.
Tiziana has submitted a patent applicationon potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival.
The Company employs a lean and virtual research and development model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.
Corporate Strategy
— Continue the clinical development of intranasal administration of Foralumab for neurodegenerative disease indications:
- Secondary Progressive, Multiple Sclerosis
- Alzheimer’s
- Amyotrophic Lateral Sclerosis (ALS)
— Commence Phase 2 clinical trial after successfully receiving their Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients.
— Submit an Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients.
— Seek orphan drugs fast track or breakthrough designation for the Company’s product candidates where warranted.
Intranasal Foralumab Pipeline
Grab Sources And More: TLSA Website.TLSA Presentation.
—–
And as I mentioned previously, (Nasdaq: TLSA) has several potential catalysts we’re tracking. Check them out:
#1. TLSA Potential Catalyst – The Company Celebrates Peer-Reviewed Success Validating Foralumab’s Clinical Promise.
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology.
The publication, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” details the comprehensive positive results previously announced by the Company on May 6, 2025. This marks the first study to integrate TSPO-PET imaging, proteomics, and clinical assessments in na-SPMS, highlighting nasal foralumab’s novel mechanism in addressing progression independent of relapse activity (PIRA)—a critical unmet need in multiple sclerosis (MS) treatment.
…
“This peer-reviewed publication in a leading neurology journal represents a major milestone and external validation of intranasal foralumab’s therapeutic potential in secondary progressive MS,” said Tanuja Chitnis, M.D., Principal Investigator and Senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system.“The integration of advanced imaging, immune profiling, and clinical outcomes underscores how nasal foralumab uniquely targets CNS inflammation through mucosal tolerance, offering hope for patients with limited options.”
…
“We are thrilled that these groundbreaking results have now been peer-reviewed and published, reinforcing our confidence in intranasal foralumab as a potential paradigm-shifting therapy for progressive MS and beyond,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences.
—–
#2. TLSA Potential Catalyst – An Analyst $8 Target Suggests Triple-Digit Potential Upside From Current Chart Levels.
Back in November, Lucid Capital Markets provided a key update on TLSA.
In the update, Lucid reiterated an $8.00 targeton TLSA.
From Friday’s close, that target represents a potential 390% upside.
Report highlights:
Tiziana Life Sciences (TLSA, Buy) announced that its Phase 2 study of intranasal foralumab for amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. Supported by an ALS Association grant, the trial will be led by Drs. Suma Babu and James Berry and will enroll patients across multiple US sites within the NEALS Consortium. Promising therapies emerging from the MyMatch Program may move into future arms of the HEALEY ALS Platform Trial, a large, ongoing late-stage efficacy platform, or proceed directly to a standalone Phase 3 study.
—–
#3. TLSA Potential Catalyst – 2 Separate Insiders Make Aggressive Purchases Highlighting What Could Be Significant Confidence In The Company.
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 97,687 common shares, bringing his total holding to 43,374,830 common shares, which is 36.08%of issued share capital.
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common st-ock in the open market. This brings his current purchased shares total to 357,848.
—–
#4. TLSA Potential Catalyst – A Major Milestone Is Achieved With First Patient Dosing In Critical Phase 2 Trial.
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
- First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial
- Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This milestone follows the Company’s December 12, 2025 announcement that enrolment had begun and the first patient was expected to be dosed imminently. The Phase 2 trial evaluates intranasal foralumab both as monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab (Leqembi®) or donanemab, in patients with early AD.
The trial is supported by TSPO-PET imaging data demonstrating persistent and widespread microglial activation—a hallmark of neuroinflammation—in Alzheimer’s patients, even after amyloid plaque reduction with lecanemab. This evidence underscores the need for therapies targeting residual neuroinflammation, which intranasal foralumab is designed to address by modulating immune responses and calming activated microglia.
Gabriele Cerrone, Chairman & Founder of Tiziana Life Sciences stated, “Dosing the first patient marks a pivotal moment in exploring a novel immunomodulatory approach to Alzheimer’s disease. Our prior TSPO-PET data in multiple sclerosis patients showed that intranasal foralumab can significantly reduce microglial activation, and we are eager to evaluate its potential impact—alone or combined with anti-amyloid treatments—in slowing disease progression in early AD.”
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented, “We are thrilled to have rapidly advanced from enrolment to first patient dosing in this important Phase 2 trial. This achievement reflects the dedication of our team and clinical sites, as well as the urgent need for new treatment strategies that go beyond amyloid clearance to target chronic neuroinflammation. We look forward to continuing enrollment and generating data that could redefine disease modification in Alzheimer’s disease.”
—–
#5. TLSA Potential Catalyst – The Company Recently Announced It Will Advance A 2nd Asset Following An Explosive Industry Acquisition.
Tiziana to Advance TZLS-501 – Its Fully Human IL-6R Monoclonal Antibody
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4Bn. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.
TZLS-501 is a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms of IL-6R. This dual mechanism of action not only blocks IL-6R signaling but also reduces circulating IL-6 cytokines, which are recognized drivers of inflammation, lung damage, and chronic fibrosis. Tiziana sees potential to develop TZLS-501 as a monotherapy, or in combination with its lead candidate, foralumab, as well as with other anti-inflammatory and anti-infective agents.
…
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented, “Novartis’ recent acquisition of Tourmaline demonstrates how IL-6 therapy is increasingly valued in treating systemic inflammation and related diseases. While intranasal foralumab remains our lead program and primary focus, we are reviewing development opp’s for TZLS-501 as a complementary asset. Our fully human IL-6 mAb has always been an exciting asset. With recent market developments, we feel it is an opportune time to explore TZLS-501’s development. Its unique ability to address both membrane-bound and soluble IL-6 signaling, positions it as a potentially powerful therapy for acute and chronic inflammatory conditions.”
—–
(Nasdaq: TLSA) Recap – 5 Potential Catalysts On Our Radar
#1. The Company Celebrates Peer-Reviewed Success Validating Foralumab’s Clinical Promise.
#2. An Analyst $8 Target Suggests Triple-Digit Potential Upside From Current Chart Levels.
#3. 2 Separate Insiders Make Aggressive Purchases Highlighting What Could Be Significant Confidence In The Company.
#4. A Major Milestone Is Achieved With First Patient Dosing In Critical Phase 2 Trial.
#5. The Company Recently Announced It Will Advance A 2nd Asset Following An Explosive Industry Acquisition.
—–
Now official: coverage has been kicked-off on Tiziana Life Sciences, Ltd. (Nasdaq: TLSA).
Be on the lookout for updates coming shortly. Talk again soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/25/2026 and ending on 01/26/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (TLSA:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/tlsa-xdmli/#details
SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US
Unsubscribe | Update Profile | Constant Contact Data Notice
